 |
BioWorld-International-2008-10-15
In Times of Financial Turmoil, Partnering Remains a Constant
Endotis Pharma Obtains R&D of €4.5M from Public Sources
No Abstract
BioWorld International Correspondent
PARIS - Endotis Pharma, which is developing small-glyco drugs for applications in thrombosis and oncology, has obtained public funding of €4.5 million (US6.1 million) from three sources to finance ongoing research programs.
In Times of Financial Turmoil, Partnering Remains a Constant
LONDON - When the going gets tough, the tough get going. "That title was fixed some weeks ago, but it turns out to be more relevant than I ever imagined," said the keynote speaker David Brennan, CEO of AstraZeneca plc, addressing BioPartnering Europe delegates Monday. (BioWorld International)